GRCE
NASDAQ · Pharmaceuticals
Grace Therapeutics Inc
$4.42
+0.04 (+0.91%)
Open$4.36
Previous Close$4.38
Day High$4.70
Day Low$4.35
52W High$4.71
52W Low$1.75
Volume—
Avg Volume549.9K
Market Cap68.40M
P/E Ratio—
EPS$-0.36
SectorPharmaceuticals
Analyst Ratings
Strong Buy
8 analysts
Price Target
+422.4% upside
Current
$4.42
$4.42
Target
$23.09
$23.09
$18.68
$23.09 avg
$33.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.56M | 18.44M | 15.17M |
| Net Income | 2.85M | 2.16M | 2.15M |
| Profit Margin | 14.6% | 11.7% | 14.2% |
| EBITDA | 5.50M | 5.11M | 4.77M |
| Free Cash Flow | 2.45M | 3.17M | 1.86M |
| Rev Growth | +16.3% | +19.0% | +18.1% |
| Debt/Equity | 0.50 | 0.57 | 0.59 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |